Tryptophan, adenosine, neurodegeneration and neuroprotection

Metabolic Brain Disease

Volumn 22, Issue 3-4, 2007, Pages 337-352

  Stone, T W ^a   Forrest, C M ^a   Mackay, G M ^a   Stoy, N ^b   Darlington, L G ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b EPSOM GENERAL HOSPITAL   (United Kingdom)

Author keywords

Glutamate; Ischaemia; Neurodegeneration; Neuroprotection; NMDA

Indexed keywords

ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; FREE RADICAL; GLUTAMATE RECEPTOR; KYNURENINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NICOTINAMIDE; NICOTINIC RECEPTOR; PURINE; QUINOLINIC ACID; TRYPTOPHAN;

BRAIN DYSFUNCTION; BRAIN INJURY; CALCIUM TRANSPORT; CATABOLISM; CONFERENCE PAPER; GLIA CELL; HEPATIC ENCEPHALOPATHY; HUMAN; IMMUNOCOMPETENT CELL; MACROPHAGE; METABOLIC DISORDER; METABOLITE; NERVE DEGENERATION; NEUROPROTECTION; NEUROTRANSMITTER RELEASE; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS;

ADENOSINE; ANIMALS; HEPATIC ENCEPHALOPATHY; HUMANS; KYNURENINE; NAD; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; QUINOLINIC ACID; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, PURINERGIC P1; TRYPTOPHAN;

EID: 35449003309     PISSN: 08857490     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11011-007-9064-3     Document Type: Conference Paper

References (120)

1. Albrecht J, Wegrzynowicz M (2005) Endogenous neuroprotectants in ammonia toxicity in the central nervous system: facts and hypotheses. Metab Brain Dis 20:253-263
2. Andine P, Rudolphi KA, Fredholm BB, Hagberg H (1990) Effect of propentofylline (HWA285) in extracellular purines and excitatory amino acids in CA1 of rat hippocampus during transient ischemia. Br J Pharmacol 100:814-818
3. Arvin B, Neville LF, Pan J, Roberts PJ (1989) 2-Chloroadenosine attenuates kainic acid-induced toxicity within the rat striatum: relationship to release of glutamate and Ca2+ influx. Br J Pharmacol 98:225-235
4. Baratte S, Molinari A, Veneroni O, Speciale C, Benatti L, Salvati P (1998) Temporal and spatial changes of quinolinic acid immunoreactivity in the gerbil hippocampus following transient cerebral ischemia. Mol Brain Res 59:50-57
5. Bartrup JT, Stone TW (1990) Activation of NMDA receptor-coupled channels suppresses the inhibitory action of adenosine on hippocampal slices. Brain Res 530:330-334
6. Basile AS, Saito K, Almardini H, Record CO, Hughes RD, Harrison P, Williams R, Li Y, Heyes MP (1995) The relationship between plasma and brain quinolinic acid levels and the severity of hepatic-encephalopathy. Gastroenterology 108:818-823
7. 2A receptor antagonists. Br J Pharmacol 135:1435-1442
8. Behan WMH, McDonald M, Darlington LG, Stone TW (1999) Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl. Br J Pharmacol 128:1754-1760
9. Bell MJ, Kochanek PM, Heyes MP, Wisniewski SR, Sinz EH, Clark RSB, Blight AR, Marion DW, Adelson PD (1999) Quinolinic acid in the cerebrospinal fluid of children after traumatic brain injury. Crit Care Med 27:493-497
10. Bergqvist PBF, Heyes MP, Bugge M, Bengtsson F (1995) Brain quinolinic acid in chronic experimental hepatic-encephalopathy-effects of an exogenous ammonium acetate challenge. J Neurochem 65:2235-2240
11. Bergqvist PBF, Heyes MP, Apelqvist G, Butterworth RF, Bengtsson F (1996) Brain extracellular quinolinic acid in chronic experimental hepatic encephalopathy as assessed by in vivo microdialysis: acute effects of L-tryptophan. Neuropsychopharmacology 15:382-389
12. Birch PJ, Grossman CJ, Hayes AG (1988) Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine site. Eur J Pharmacol 154:85-87
13. Blight AR, Saito K, Heyes MP (1993) Increased levels of the excitotoxin quinolinic acid in spinal cord following contusion injury. Brain Res 632:314-316
14. Blight AR, Cohen TI, Saito K, Heyes MP (1995) Quinolinic acid accumulation and functional deficits following experimental spinal cord injury. Brain 118:735-752
15. Blight AR, Leroy EC Jr, Heyes MP (1997) Quinolinic acid accumulation in injured spinal cord: time course, distribution, and species differences between rat and guinea pig. J Neurotrauma 14:89-98
16. Butcher SP, Bullock R, Graham DI, McCulloch J (1990) Correlation between amino acid release and neuropathologic outcome in rat brain following middle cerebral artery occlusion. Stroke 21:1727-1733
17. 2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci 19:9192-9200
18. Connick JH, Stone TW (1989) Quinolinic acid neurotoxicity: protection by intracerebral phenylisopropyl adenosine (PIA) and potentiation by hypotension. Neurosci Lett 101:191-196
19. 1-receptors, guanine nucleotide and forskolin binding sites following transient brain ischaemia: a quantitative autoradiographic study. Brain Res 491:212-226
20. De Mendonca A, Sebastiao AM, Ribeiro JA (1995) Inhibition of NMDA receptor-mediated currents in isolated rat hippocampal neurons by adenosine A(1) receptor activation. Neuroreport 6:1097-1100
21. Dykens JA, Sullivan SG, Stern A (1987) Oxidative reactivity of the tryptophan metabolites 3-hydroxyanthranilate, cinnabarinate, quinolinate and picolinate. Biochem Pharmacol 36:211-217
22. Dykens JA, Sullivan SG, Stern A (1989) Glucose metabolism and hemoglobin reactivity in human red blood cells exposed to the tryptophan metabolites 3-hydroxyanthranilate, quinolinate and picolinate. Biochem Pharmacol 38:1555-1562
23. Eastman CL, Guilarte TR (1989) Cytotoxicity of 3-hydroxykynurenine in a neuronal hybrid cell line. Brain Res 495:225-231
24. Eastman CL, Guilarte TR (1990) The role of hydrogen peroxide in the in vitro cytotoxicity of 3-hydroxykynurenine. Neurochem Res 15:1101-1107
25. Espey MG, Moffett JR, Namboodiri MAA (1995) Temporal and spatial changes of quinolinic acid immunoreactivity in the immune system of lipopolysaccharide- stimulated mice. J Leukoc Biol 57:199-206
26. Espey MG, Chernyshev ON, Reinhard JF Jr, Namboodiri MAA, Colton CA (1997) Activated human microglia produce the excitotoxin quinolinic acid. Neuroreport 8:431-434
27. Galarraga E, Surmeier DJ, Kitai ST (1990) Quinolinate and kainate neurotoxicity in neostriatal cultures is potentiated by coculturing with neocortical neurons. Brain Res 512:269-276
28. Gao Y, Phillis JW (1994) CGS 15943, an adenosine A2 receptor antagonist, reduces cerebral ischemic injury in the mongolian gerbil. Life Sci 55:PL61-PL65
29. Giulian D, Vaca K, Noonan CA (1990) Secretion of neurotoxins by mononuclear phagocytes infected with HIV-1. Science 250:1593-1596
30. Giulian D, Wendt E, Vaca K, Noonan CA (1993) The envelope glycoprotein of human immunodeficiency virus type-1 stimulates release of neurotoxins from monocytes. Proc Natl Acad Sci U S A 90:2769-2773
31. Hagberg H, Andersson P, Lacarewicz J, Jacobson I, Butcher S, Sandberg M (1987) Extracellular adenosine, inosine, hypoxanthine, and xanthine in relation to tissue nucleotides and purines in rat striatum during transient ischaemia. J Neurochem 49:227-231
32. 1 adenosine receptor agonist on the neurochemical, behavioural and histological consequences of ischaemia. Brain Res 641:217-224
33. Heyes MP, Lackner A (1990) Increased cerebrospinal fluid quinolinic acid, kynurenic acid and L-kynurenine in acute septicemia. J Neurochem 55:338-341
34. Heyes MP, Nowak TS Jr (1990) Delayed increases in regional brain quinolinic acid follow transient ischemia in the gerbil. J Cereb Blood Flow Metab 10:660-667
35. Heyes MP, Quearry BJ, Markey SP (1989) Systemic endotoxin increases L-tryptophan, 5-hydroxyindoleacetic acid, 3-hydroxykynurenine and quinolinic acid content of mouse cerebral-cortex. Brain Res 491:173-179
36. Heyes MP, Saito K, Crowley JS, Davis LE, Demitrack MA, Der M, Dilling LA, Elia J, Kruesi MJP, Lackner A, Larsen SA, Lee K, Leonard HL, Markey SP, Martin A, Milstein S, Mouradian MM, Pranzatelli MR, Quearry BJ, Salazar A, Smith M, Straus SE, Sunderland T, Swedo SE, Tourtellotte WW (1992) Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurologic disease. Brain 115:1249-1273
37. Heyes MP, Achim CL, Wiley CA, Major EO, Saito K, Markey SP (1996) Human microglia convert L-tryptophan into the neurotoxin quinolinic acid. Biochem J 320:595-597
38. Hiraku Y, Inoue S, Oikawa S, Yamamoto K, Tada S, Nishino K, Kawanishi S (1995) Aluminium-mediated oxidative damage to cellular and isolated dna by certain tryptophan-metabolites. Carcinogenesis 16:349-356
39. Holt DE, Washabau RJ, Djali S, Dayrell-Hart B, Drobatz KJ, Heyes MP, Robinson MB (2002) Cerebrospinal fluid glutamine, tryptophan, and tryptophan metabolite concentrations in dogs with portosystemic shunts. Am J Vet Res 63:1167-1171
40. Hosseinzadeh H, Stone TW (1998) Tolbutamide blocks postsynaptic but not presynaptic effects of adenosine on hippocampal CA1 neurons. J Neural Transm 105:161-172
41. Jalan R, Shawcross D, Davies N (2003) The molecular pathogenesis of hepatic encephalopathy. Int J Biochem Cell Biol 35:1175-1181
42. 2A receptor antagonist. Brain Res 800:328-335
43. 2A receptor agonists and antagonists. Neuroscience 85:229-237
44. Kerr SJ, Armati PJ, Brew BJ (1995) Neurocytotoxicity of quinolinic acid in human brain cultures. J Neurovirol 1:375-380
45. Kerr SJ, Armati PJ, Guillemin GJ, Brew BJ (1998) Chronic exposure of human neurones to quinolinic acid results in neuronal changes consistent with AIDS dementia complex. AIDS 12:355-363
46. Khaspekov L, Kida E, Victorov I, Mossakowski MJ (1989) Neurotoxic effect induced by quinolinic acid in dissociated cell culture of mouse hippocampus. J Neurosci Res 22:150-157
47. Kim JP, Choi DW (1987) Quinolinate neurotoxicity in cortical cell culture. Neuroscience 23:423-432
48. Kitano T, Matsumura S, Seki T, Hikida T, Sakimura K, Nagano T, Mishina M, Nakanishi S, Ito S (2004) Characterization of N-methyl-D-aspartate receptor subunits involved in acute ammonia toxicity. Neurochem Int 44:83-90
49. Klejman A, Wegrzynowicz M, Szatmari EM, Mioduszewska B, Hetman M, Albrecht J (2005) Mechanisms of ammonia-induced cell death in rat cortical neurons: roles of NMDA receptors and glutathione. Neurochem Int 47:51-57
50. Kocki T, Dolinska M, Dybel A, Urbanska EM, Turski WA, Albrecht J (2002) Regulation of kynurenic acid synthesis in C6 glioma cells. J Neurosci Res 68:622-626
51. Kosenko E, Llansola M, Montoliu C, Monfort P, Rodrigo R, Hernandez-Viadel M, Erceg S, Sanchez-Perez AM, Felipo V (2003) Glutamine synthetase activity and glutamine content in brain: modulation by NMDA receptors and nitric oxide. Neurochem Int 43:493-499
52. Kosenko E, Montoliu C, Giordano G, Kaminsky Y, Venediktova N, Buryanov Y, Felipo V (2004) Acute ammonia intoxication induces an NMDA receptor-mediated increase in poly(ADP-ribose) polymerase level and NAD(+) metabolism in nuclei of rat brain cells. J Neurochem 89:1101-1110
53. Latini S, Bordoni F, Pedata F, Corradetti R (1999) Extracellular adenosine concentrations during in vitro ischaemia in rat hippocampal slices. Br J Pharmacol 127:729-739
54. Lau Y-S, Mouradian MM (1993) Protection against acute MPTP-induced dopamine depletion in mice by adenosine. J Neurochem 60:768-771
55. Lees GJ (1993) The possible contribution of microglia and macrophages to delayed neuronal death after ischemia. J Neurol Sci 114:119-122
56. MacGregor DG, Stone TW (1993) Inhibition by the adenosine analogue, (R-)-N6-phenylisopropyladenosine, of kainic acid neurotoxicity in rat hippocampus after systemic administration. Br J Pharmacol 109:316-321
57. MacGregor DG, Miller WJ, Stone TW (1993) Mediation of the neuroprotective action of R-phenylisopropyladenosine through a centrally located adenosine A1 receptor. Br J Pharmacol 110:470-476
58. MacGregor DG, Jones PA, Maxwell WL, Graham DI, Stone TW (1996) Prevention by a purine analogue of kainate-induced neuropathology in rat hippocampus. Brain Res 725:115-120
59. Matsusue E, Kinoshita T, Ohama E, Ogawa T (2005) Cerebral cortical and white matter lesions in chronic hepatic encephalopathy: MR-pathologic correlations. AJNR Am J Neuroradiol 26:347-351
60. Michaelis ML, Michaelis EK, Myers SL (1979) Adenosine modulation of synaptosomal dopamine release. Life Sci 24:2083-2092
61. Moffett JR, Espey MG, Gaudet SJ, Namboodiri MAA (1993) Antibodies to quinolinic acid reveal localization in select immune cells rather than neurones or astroglia. Brain Res 623:337-340
62. Moffett JR, Espey MG, Namboodiri MAA (1994) Antibodies to quinolinic acid and the determination of its cellular distribution within the rat immune system. Cell Tissue Res 278:461-469
63. Moffett JR, Els T, Espey MG, Walter SA, Streit WJ, Namboodiri MAA (1997) Quinolinate immunoreactivity in experimental rat brain tumors is present in macrophages but not in astrocytes. Exp Neurol 144:287-301
64. 2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats. Neuroreport 9:3955-3959
65. Moroni F, Lombardi G, Carlà V, Pellegrini D, Carassale GL, Cortesini C (1986a) Content of quinolinic acid and of other tryptophan- metabolites increases in brain-regions of rats used as experimental-models of hepatic-encephalopathy. J Neurochem 46:869-874
66. Moroni F, Lombardi G, Carla V, Pellegrini D, Carassale GJ, Cortesini C (1986b) Increase in the content of quinolinic acid in cerebrospinal-fluid and frontal-cortex of patients with hepatic-failure. J Neurochem 47:1667-1671
67. Nakagami Y, Saito H, Katsuki H (1996) 3-hydroxykynurenine toxicity on the rat striatum in vivo. Jpn J Pharmacol 71:183-186
68. Nakai M, Qin ZH, Wang Y, Chase TN (1999) Free radical scavenger OPC-14117 attenuates quinolinic acid-induced NFκB activation and apoptosis in rat striatum. Mol Brain Res 64:59-68
69. Nakao N, Brundin P (1997) Effects of alpha-phenyl-t-butyl nitrone on neuronal survival and motor function following intrastriatal injections of quinolinate or 3-nitropropionic acid. Neuroscience 76:749-761
70. Namboodiri AMA, Venkateshan CNS, Narayanan R, Blinder K, Moffett JR, Gajdusek DC, Gravell M, Gibbs J (1996) Increased quinolinate immunoreactivity in the peripheral blood macrocytes/macrophages from SIV-infected monkeys. J Neurovirol 2:433-438
71. Nikbakht M-R, Stone TW (2001) Suppression of presynaptic responses to adenosine by activation of NMDA receptors. Eur J Pharmacol 427:13-25
72. Norenberg W, Wirkner K, Illes P (1997) Effect of adenosine and some of its structural analogues on the conductance of NMDA receptor channels in a subset of rat neostriatal neurons. Br J Pharmacol 122:71-80
73. O'Kane EM, Stone TW (1998) Interactions between A1 and A2 adenosine receptor-mediated responses in the rat hippocampus in vitro. Eur J Pharmacol 362:17-25
74. Okuda S, Nishiyama N, Saito H, Katsuki H (1996) Hydrogen peroxide-mediated neuronal cell death induced by an endogenous neurotoxin, 3-hydroxykynurenine. Proc Natl Acad Sci U S A 93:12553-12558
75. Okuda S, Nishiyama N, Saito H, Katsuki H (1998) 3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J Neurochem 70:299-307
76. 2A receptors and neuroprotection. Ann N Y Acad Sci 825:30-48
77. 2A adenosine receptor antagonists on motor dysfunction and neurodegenerative processes. Drug Dev Res 52:379-386
78. Pearson SJ, Reynolds GP (1991) Determination of 3-hydroxykynurenine in human brain and plasma by HPLC with electrochemical detection. Increased concentrations in hepatic encephalopathy. J Chromatogr 565:436-440
79. Pearson SJ, Reynolds GP (1992) Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease. Neurosci Lett 144:199-201
80. Pearson SJ, Meldrum A, Reynolds GP (1995) An investigation of the activities of 3-hydroxykynureninase and kynurenine aminotransferase in the brain in Huntington's disease. J Neural Transm 102:67-73
81. Pemberton LA, Kerr SJ, Smythe G, Brew BJ (1997) Quinolinic acid production by macrophages stimulated with IFN-γ, TNF-α and IFN-α. J Interferon Cytokine Res 17:589-595
82. Perkins MN, Stone TW (1982) An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res 247:184-187
83. 2A adenosine receptor antagonists on cerebral ischemic injury in the gerbil. Brain Res 705:79-84
84. Pierri M, Vaudan E, Sager T, Englund U (2005) KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse. Neuropharmacology 48:517-524
85. Popovich PG, Reinhard JF, Flanagan EM, Stokes BT (1994) Elevation of the neurotoxin quinolinic acid occurs following spinal cord trauma. Brain Res 633:348-352
86. Rao KVR, Panickar K, Jayakumar AR, Norenberg MD (2005a) Astrocytes protect neurons from ammonia toxicity. Neurochem Res 30:1311-1318
87. Rao KVR, Jayakumar AR, Norenberg MD (2005b) Role of oxidative stress in the ammonia-induced mitochondrial permeability transition in cultured astrocytes. Neurochem Int 47:31-38
88. Regenold JT, Illes P (1990) Inhibitory adenosine A1-receptors on rat locus coeruleus neurones. An intracellular electrophysiological study. Naunyn Schmiedebergs Arch Pharmacol 341:225-231
89. Reinhard JF Jr (1998) Altered tryptophan metabolism in mice with herpes simplex virus encephalitis: increases in spinal cord quinolinic acid. Neurochem Res 23:661-665
90. Reynolds GP, Pearson SJ (1989) Increased brain 3-hydroxykynurenine in Huntington's disease. Lancet 2:979-980
91. Rios C, Santamaria A (1991) Quinolinic acid is a potent lipid peroxidant in rat brain homogenates. Neurochem Res 16:1139-1143
92. Robinson MB, Heyes MP, Anegawa NJ, Gorry E, Djali S, Mellits ED, Batshaw ML (1992) Quinolinate in brain and cerebrospinal-fluid in rat models of congenital hyperammonemia. Pediatr Res 32:483-488
93. Rudolphi KA, Schubert P, Parkinson FE, Fredholm BB (1992) Adenosine and brain ischemia. Cerebrovasc Brain Metab Rev 4:346-369
94. Saito K, Markey SP, Heyes MP (1992) Effects of immune activation on quinolinic acid and neuroactive kynurenines in the mouse. Neuroscience 51:25-39
95. Saito K, Markey SP, Heyes MP (1994) 6-Chloro-D,L-tryptophan,4-chloro-3- hydroxy-anthranilate and dexamethasone attentuate quinolinic acid accumulation in brain and blood following systemic immune activation. Neurosci Lett 178:211-215
96. Saran T, Hilgier W, Kocki T, Urbanska EM, Turski WA, Albrecht J (1998) Acute ammonia treatment in vitro and in vivo inhibits the synthesis of a neuroprotectant kynurenic acid in rat cerebral cortical slices. Brain Res 787:348-350
97. Saran T, Hilgier W, Urbanska EM, Turski WA, Albrecht J (2004) Kynurenic acid synthesis in cerebral cortical slices of rats with progressing symptoms of thioacetamide-induced hepatic encephalopathy. J Neurosci Res 75:436-440
98. Sardar AM, Bell JE, Reynolds GP (1995) Increased concentrations of the neurotoxin 3-hydroxykynurenine in the frontal cortex of HIV-1-positive patients. J Neurochem 64:932-935
99. Scholz KP, Miller RJ (1991) Inhibition of quantal transmitter release in the absence of calcium influx by a G protein-linked adenosine receptor at hippocampal synapses. Neuron 8:1139-1150
100. Schwarcz R, Whetsell WO Jr, Mangano RM (1983) Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 219:316-318
101. Schwarcz R, Okuno E, White RJ, Bird ED, Whetsell WO Jr (1988) 3-Hydroxyanthranilate oxygenase activity is increased in the brains of Huntington disease victims. Proc Natl Acad Sci U S A 85:4079-4081
102. Shahraki A, Stone TW (2004) Blockade of presynaptic adenosine A1 responses by nitric oxide and superoxide in rat hippocampus. Eur J Neurosci 20:719-728
103. 2A receptor agonist CGS21680. Drug Dev Res 39:108-114
104. Sinz EH, Kochanek PM, Heyes MP, Wisniewski SR, Bell MJ, Clark RSB, Dekosky ST, Blight AR, Marion DW (1998) Quinolinic acid is increased in CSF and associated with mortality after traumatic brain injury in humans. J Cereb Blood Flow Metab 18:610-615
105. Southgate GS, Daya S, Potgieter B (1998) Melatonin plays a protective role in quinolinic acid-induced neurotoxicity in the rat hippocampus. J Chem Neuroanat 14:151-156
106. Spignoli G, Pedata F, Pepeu G (1984) A1 and A2 adenosine receptors modulate acetylcholine release from brain slices. Eur J Pharmacol 97:341-342
107. Stone TW (1993) The neuropharmacology of quinolinic acid and kynurenic acid. Pharmacol Rev 45:309-379
108. Stone TW (2000a) The development and therapeutic potential of kynurenic acid and kynurenine derivatives for CNS neuroprotection. Trends Pharmacol Sci 21:149-154
109. Stone TW (2000b) Inhibitors of the kynurenine pathway. Eur J Med Chem 35:179-186
110. Stone TW (2001) Kynurenines in the CNS: from endogenous obscurity to clinical relevance. Prog Neurobiol 64:185-218
111. Stone TW, Perkins MN (1981) Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur J Pharmacol 72:411-412
112. Stone TW, Darlington LG (2002) Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov 1:609-620
113. Sung V, Venkateshan CN, Williamson L, Ward R, Espey M, Gibbs CJ Jr, Moffett JR, Namboodiri MAA (1997) Immune-electron microscopy reveals that the excitotoxin quinolinate is associated with the plasma membrane in human peripheral blood monocytes/macrophages. Cell Tissue Res 290:633-639
114. Tominaga K, Shibata S, Watanabe S (1992) A neuroprotective effect of adenosine A1-receptor agonists on ischemia-induced decrease in 2-deoxyglucose uptake in rat hippocampal slices. Neurosci Lett 145:67-70
115. von Lubitz DKEJ, Dambrosia JM, Redmond DJ (1989) Protective effect of cyclohexyladenosine in treatment of cerebral ischaemia in gerbils. Neuroscience 30:451-462
116. 2A receptor agonist and antagonist. Eur J Pharmacol 287:295-302
117. von Lubitz DJKE, Lin RCS, Bischofberger N, Beenhakker M, Boyd M, Lipartowska R, Jacobson KA (1999) Protection against ischemic damage by adenosine amine congener, a potent and selective adenosine A1 receptor agonist. Eur J Pharmacol 369:313-317
118. Whetsell WO Jr, Schwarcz R (1989) Prolonged exposure to submicromolar concentrations of quinolinic acid causes excitotoxic damage in organotypic cultures of rat corticostriatal system. Neurosci Lett 97:271-275
119. Winn HR, Rubio R, Berne RM (1979) Brain adenosine production in the rat during 60 seconds of ischemia. Circ Res 45:486-492
120. Yamamoto H, Shindo I, Egawa B, Horiguchi K (1994) Kynurenic acid is decreased in cerebrospinal fluid of patients with infantile spasms. Pediatr Neurol 10:9-12